Detail
| LncRNA Name | SOX2OTV7 |
| Synonyms | NA |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✔ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | osteosarcoma |
| ICD-0-3 | M9180/3 |
| Methods | qPCR, Western blot, in vitro knockdown |
| Sample | cell lines (U2OS and SaoS2, U-87 MG ) |
| Expression Pattern | down-regulated |
| Function Description | EGCG targeting LncRNA SOX2OT variant 7 produced synergistic effects with Doxorubicin on osteosarcoma cell growth inhibition. On the one hand, EGCG could reduce the Doxorubicin-induced pro-survival autophagy through decreasing SOX2OT variant 7 to improve the growth inhibition of Doxorubicin. On the other hand, EGCG could partially inactivate Notch3/DLL3 signaling cascade targeting SOX2OT variant 7 to reduce the stemness then abated drug-resistance of osteosarcoma cells. |
| Pubmed ID | 29475441 |
| Year | 2018 |
| Title | SOX2OT variant 7 contributes to the synergistic interaction between EGCG and Doxorubicin to kill osteosarcoma via autophagy and stemness inhibition. |
| External Links |
| Links for SOX2OTV7 | GenBank HGNC lncrnadb Noncode |
| Links for osteosarcoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.